Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00205
|
|||||
| Drug Name |
Riluzole
|
|||||
| Synonyms |
2-Amino-6-(trifluoromethoxy)-benzothiazole; 2-Amino-6-(trifluoromethoxy)benzothiazole; 2-Amino-6-trifluoro-methoxybenzothiazole; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-amino-6-(trifluoromethoxyl)benzothiazole; 2-amino-6-trifluoromethoxybenzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 6-trifluoromethoxybenzothiazole-2-yl-amine; ALBB-006046; Amino-2 trifluoromethoxy-6 benzothiazole; Amino-2 trifluoromethoxy-6 benzothiazole [French]; BF-37; PK-26124; PK-26124, RP-54274, Rilutek, Riluzole; R-116; RP 54274; RP-54274; Rilutek; Rilutek (TN); Riluzol; Riluzol [INN-Spanish]; Riluzole (JAN/USAN/INN); Riluzole HCl; Riluzole [USAN:INN]; Riluzolum; Riluzolum [INN-Latin]; ZERO/001785
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Amyotrophic lateral sclerosis [ICD11:8B60.0] | Approved | [1] | |||
| Therapeutic Class |
Anticonvulsants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C8H5F3N2OS
|
|||||
| Canonical SMILES |
C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
|
|||||
| InChI |
InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
|
|||||
| InChIKey |
FTALBRSUTCGOEG-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 1744-22-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 234.2 | Topological Polar Surface Area | 76.4 | ||
| Heavy Atom Count | 15 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
3.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10139
,11111722
,11111723
,11113346
,11120296
,11120784
,11121272
,11466195
,11467315
,11484335
,11485690
,11488366
,12013649
,14773880
,17405620
,24278006
,26679689
,26751529
,29224139
,3158794
,46508094
,47440015
,47515108
,47588789
,47810535
,47810536
,48034873
,48334245
,49698375
,49890627
,50100339
,50104104
,50104105
,53778170
,57322593
,57566695
,57641351
,7379879
,74971764
,7735262
,7847840
,7980518
,8153119
,85089205
,85171908
,85231207
,855844
,85787918
,85788320
,866566
|
|||||
| ChEBI ID |
CHEBI:8863
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Riluzole was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett. 2009 Mar 6;452(1):12-6. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.